Product Information
Registration Status: ActiveSIN15620P
DEFUZIN CREAM 2% W/W is approved to be sold in Singapore with effective from 2019-02-01. It is marketed by APEX PHARMA MARKETING PTE LTD, with the registration number of SIN15620P.
This product contains Fusidic Acid 2% w/w in the form of CREAM. It is approved for TOPICAL use.
This product is manufactured by XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD in MALAYSIA.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis.
Indication
For the treatment of bacterial infections.
Mechanism of Action
Fusidic acid works by interfering with bacterial protein synthesis, specifically by preventing the translocation of the elongation factor G (EF-G) from the ribosome. It also can inhibit chloramphenicol acetyltransferase enzymes.
Pharmacokinetics
- Absorption
- Sodium fusidic acid tablets have a 91% oral bioavailability. Absorption of the film-coated tablets is complete when compared to a solution, however oral absorption is variable. Oral fusidic acid hemihydrate (suspension) achieved a 22.5% bioavailability in pediatric patients following a 20 milligram/kilogram dose.
- Distribution
- Metabolism
- Metabolites include dicarboxylic ester/acid, 3-keto fusidic acid, hydroxy fusidic acid, glucuronide fusidic acid and a glycol metabolite.
- Elimination
Active Ingredient/Synonyms
Fucidate | Fucidin acid | Fusidate | Fusidic acid | Fusidine | Ramycin | Fusidic Acid |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.